Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.
Jenifer Vija
Advertisement
Jenifer Vija is scientific director, bioanalysis, at Charles River Laboratories.
Articles by Jenifer Vija
Advertisement
Latest Updated Articles
Emerging Therapies Test Existing Bioanalytical MethodsPublished: April 15th 2019 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
2
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
3
AstraZeneca Next to Agree to MFN Deal: Report
4
BioPharm Weekly News Roundup—Week of Oct. 6, 2025
5
